RemeGen Balance Sheet Health
Financial Health criteria checks 3/6
RemeGen has a total shareholder equity of CN¥1.8B and total debt of CN¥2.7B, which brings its debt-to-equity ratio to 152.1%. Its total assets and total liabilities are CN¥5.3B and CN¥3.5B respectively.
Key information
152.15%
Debt to equity ratio
CN¥2.70b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥721.72m |
| Equity | CN¥1.77b |
| Total liabilities | CN¥3.54b |
| Total assets | CN¥5.31b |
Recent financial health updates
RemeGen (HKG:9995) Is Carrying A Fair Bit Of Debt
May 12
Is RemeGen (HKG:9995) Using Debt In A Risky Way?
Mar 24Is RemeGen (HKG:9995) In A Good Position To Invest In Growth?
Aug 03Recent updates
RemeGen (HKG:9995) Is Carrying A Fair Bit Of Debt
May 12RemeGen Co., Ltd.'s (HKG:9995) 68% Price Boost Is Out Of Tune With Revenues
Apr 21RemeGen Co., Ltd.'s (HKG:9995) Shares Bounce 33% But Its Business Still Trails The Industry
Mar 06The Market Doesn't Like What It Sees From RemeGen Co., Ltd.'s (HKG:9995) Revenues Yet As Shares Tumble 30%
Jan 12There's No Escaping RemeGen Co., Ltd.'s (HKG:9995) Muted Revenues Despite A 25% Share Price Rise
Nov 27Improved Revenues Required Before RemeGen Co., Ltd. (HKG:9995) Stock's 31% Jump Looks Justified
Sep 28RemeGen Co., Ltd. (HKG:9995) Just Reported Earnings, And Analysts Cut Their Target Price
Aug 20Benign Growth For RemeGen Co., Ltd. (HKG:9995) Underpins Stock's 41% Plummet
Jul 22Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet
Jun 21RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 35% But Its Business Is Yet to Catch Up
Apr 04Is RemeGen (HKG:9995) Using Debt In A Risky Way?
Mar 24RemeGen Co., Ltd. (HKG:9995) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
Feb 18Getting In Cheap On RemeGen Co., Ltd. (HKG:9995) Is Unlikely
Dec 29RemeGen Co., Ltd. (HKG:9995) Shares Could Be 34% Below Their Intrinsic Value Estimate
Oct 16Is RemeGen (HKG:9995) In A Good Position To Invest In Growth?
Aug 03Is There An Opportunity With RemeGen Co., Ltd.'s (HKG:9995) 35% Undervaluation?
Jun 22RemeGen Co., Ltd. (HKG:9995) Investors Are Less Pessimistic Than Expected
May 10Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 36%?
Mar 09RemeGen's (HKG:9995) Earnings Aren't As Good As They Appear
May 04RemeGen Co., Ltd. (HKG:9995) Analysts Just Cut Their EPS Forecasts Substantially
Apr 08Financial Position Analysis
Short Term Liabilities: 9995's short term assets (CN¥2.2B) do not cover its short term liabilities (CN¥2.3B).
Long Term Liabilities: 9995's short term assets (CN¥2.2B) exceed its long term liabilities (CN¥1.2B).
Debt to Equity History and Analysis
Debt Level: 9995's net debt to equity ratio (111.4%) is considered high.
Reducing Debt: 9995's debt to equity ratio has increased from 128.9% to 152.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 9995 has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: 9995 is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/03 09:25 |
| End of Day Share Price | 2025/06/03 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RemeGen Co., Ltd. is covered by 33 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shun Kei Law | CCB International Securities Limited |
| Zhishun Siu | CCB International Securities Limited |
| Ziyu He | China International Capital Corporation Limited |